Toro Neurovascular CEO Hyung Posalit said: “Our goal is to improve patient outcomes through innovation, and we are excited to showcase how our technology may streamline clot access and removal.

This program aimed to bridge the gap between conventional training and the evolving demands of modern neurovascular care. “The event underscored the critical importance of incorporating ...

Q'Apel Medical (Q'Apel), a private medical device company focused on revolutionizing neurovascular interventions, today announced it has received U.S. Food and Drug Administration (FDA) clearance ...